Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer
Cancer Cell · 2026
DOI: 10.1016/j.ccell.2026.05.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2026. Verfasst von Jun Liao und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-se…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Drug-tolerant persister (DTP) cells play a key role in the development of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small-cell lung cancer (NSCLC). Through comprehensive analyses, we identify that TROP2 is dynamically upregulated during TKI-induced DTP formation and functionally contributes to DTP maintenance. Mechanistically, c-Myc acts as a transcriptional repressor of TROP2, and TKI-mediated MAPK pathway inhibition reduces c-Myc levels, leading to TROP2 upregulation. Importantly, combining the TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) with osimertinib effectively suppresses DTP emergence and delays tumor relapse in preclinical models. An ongoing phase 2 trial evaluating first-line sac-TMT plus osimertinib combination therapy in patients with advanced EGFR-mutant NSCLC shows preliminary efficacy. Together, our findings establish TROP2 as a therapeutically actionable vulnerability in DTP cells and support the clinical development of TROP2-ADC combined with EGFR-TKI as a first-line strategy to delay TKI resistance and improve outcomes in EGFR-mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Thoracic Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Techno…
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
- Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- Department of Medical Oncology, Digestive and Urinary Unit, Hunan Cancer Hospital, Changsha, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liao, J., Yao, W., Yu, Y., Li, A., Huang, J., Li, X., Sun, L., Zhang, Y., Wang, Y., Qu, X., Zhao, J., Wang, H., Zhuang, W., Hu, L., Chen, X., Pang, L., Yang, M., Chen, Z., Zhang, Y., …, & Fang, W. (2026). Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.05.020
Vancouver
Liao J, Yao W, Yu Y, Li A, Huang J, Li X, et al. Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.05.020
BibTeX
@article{Liao2026,
author = {Liao, Jun and Yao, Wenxiu and Yu, Yan and Li, Anlin and Huang, Jie and Li, Xingya and Sun, Longhua and Zhang, Yongchang and Wang, Yongsheng and Qu, Xiujuan and Zhao, Jun and Wang, Haiyong and Zhuang, Weitao and Hu, Liyang and Chen, Xueyuan and Pang, Lanlan and Yang, Mengjuan and Chen, Zexin and Zhang, Yaxiong and Li, Ting and Yu, Wenyan and Zeng, Yiming and Li, Jing and Kataria, Ritesh and Blumenthal, Gideon and Akala, Omobolaji and Liu, Yanjun and Shen, Yuping and Ge, Junyou and Hong, Shaodong and Yang, Yunpeng and Zhang, Li and Fang, Wenfeng},
title = {Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2026.05.020}
}
EUVIMED